Last updated on January 2020

A Phase 2 Study of CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis

Brief description of study

This is a randomized, double-blind, placebo-controlled Phase 2A study to evaluate safety, efficacy, PK, and dose response of oral CIN-102 in adults with idiopathic and diabetic gastroparesis. The study will assess three oral doses of CIN-102 versus placebo in three separate cohorts.

Clinical Study Identifier: NCT04026997

Find a site near you

Start Over

Research site

Great Neck, NY United States
  Connect »